Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $81.82

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $81.8182.

A number of equities analysts recently issued reports on ANAB shares. HC Wainwright started coverage on shares of AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 price target on the stock. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Truist Financial upgraded shares of AnaptysBio to a “hold” rating in a research note on Wednesday, March 25th. Barclays upped their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Finally, Stifel Nicolaus upped their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $57.51 on Monday. The firm’s 50-day moving average price is $60.01 and its 200-day moving average price is $54.97. The company has a market capitalization of $1.67 billion, a PE ratio of -53.25 and a beta of 0.72. AnaptysBio has a 1-year low of $11.40 and a 1-year high of $72.36.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 11.53%. Equities analysts anticipate that AnaptysBio will post -1.35 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a share buyback program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other AnaptysBio news, Director John P. Schmid sold 20,645 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the transaction, the director owned 31,622 shares in the company, valued at approximately $1,774,310.42. This represents a 39.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Faga sold 17,679 shares of the company’s stock in a transaction dated Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the transaction, the chief executive officer owned 495,965 shares in the company, valued at $30,556,403.65. This represents a 3.44% decrease in their position. The disclosure for this sale is available in the SEC filing. 33.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Smartleaf Asset Management LLC lifted its stake in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares during the period. Larson Financial Group LLC lifted its stake in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the period. Bessemer Group Inc. lifted its stake in AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares during the period. Tower Research Capital LLC TRC lifted its stake in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. lifted its stake in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.